CA2967851C - Treating seizure with recombinant alkaline phosphatase - Google Patents

Treating seizure with recombinant alkaline phosphatase Download PDF

Info

Publication number
CA2967851C
CA2967851C CA2967851A CA2967851A CA2967851C CA 2967851 C CA2967851 C CA 2967851C CA 2967851 A CA2967851 A CA 2967851A CA 2967851 A CA2967851 A CA 2967851A CA 2967851 C CA2967851 C CA 2967851C
Authority
CA
Canada
Prior art keywords
alkaline phosphatase
use according
day
week
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2967851A
Other languages
English (en)
French (fr)
Other versions
CA2967851A1 (en
Inventor
Andre Marozsan
Denise DEVORE
Susan LIU-CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CA2967851A1 publication Critical patent/CA2967851A1/en
Application granted granted Critical
Publication of CA2967851C publication Critical patent/CA2967851C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2967851A 2014-12-05 2015-12-04 Treating seizure with recombinant alkaline phosphatase Active CA2967851C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462088025P 2014-12-05 2014-12-05
US62/088,025 2014-12-05
US201562259307P 2015-11-24 2015-11-24
US62/259,307 2015-11-24
PCT/US2015/064003 WO2016090251A1 (en) 2014-12-05 2015-12-04 Treating seizure with recombinant alkaline phosphatase

Publications (2)

Publication Number Publication Date
CA2967851A1 CA2967851A1 (en) 2016-06-09
CA2967851C true CA2967851C (en) 2024-02-27

Family

ID=55173939

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2967851A Active CA2967851C (en) 2014-12-05 2015-12-04 Treating seizure with recombinant alkaline phosphatase

Country Status (13)

Country Link
US (2) US10449236B2 (OSRAM)
EP (1) EP3226891B1 (OSRAM)
JP (1) JP6787894B2 (OSRAM)
KR (2) KR20240045379A (OSRAM)
CN (1) CN107405390A (OSRAM)
AU (1) AU2015357551B2 (OSRAM)
BR (1) BR112017011900A2 (OSRAM)
CA (1) CA2967851C (OSRAM)
CO (1) CO2017005034A2 (OSRAM)
ES (1) ES3038086T3 (OSRAM)
MX (1) MX389350B (OSRAM)
RU (1) RU2708068C2 (OSRAM)
WO (1) WO2016090251A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS WITH ALKALINE PHOSPHATASES
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) * 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CN106591255B (zh) * 2017-01-13 2019-07-02 山东省医药生物技术研究中心 人碱性磷酸酶糖蛋白的癌细胞高效表达系统及其应用
EP3592372A4 (en) * 2017-03-09 2021-01-13 Alexion Pharmaceuticals, Inc. GLYCOPROTEIN MANUFACTURING PROCESS
BR112019020506A2 (pt) 2017-03-31 2020-08-04 Alexion Pharmaceuticals, Inc. métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3965805A4 (en) 2019-05-06 2023-01-25 Synthetic Biologics, Inc. ALKALINE PHOSPHATE BASED ONCOLOGICAL TREATMENTS
KR20220111693A (ko) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
AU2021338361A1 (en) * 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR20230145120A (ko) 2021-02-12 2023-10-17 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법
JP7720105B2 (ja) * 2021-03-23 2025-08-07 学校法人日本医科大学 組織非特異型アルカリホスファターゼの送達のための遺伝子療法構築物およびその使用方法
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途
WO2025097067A2 (en) * 2023-11-02 2025-05-08 Be Biopharma, Inc. Engineered cell preparations for treatment of hypophosphatasia

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
JP2636500B2 (ja) 1990-04-20 1997-07-30 壽之 松尾 ブタ由来新規生理活性ペプチド
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP2977158B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）
JP2977159B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 カエル由来新規生理活性ペプチド（カエルｃｎｐ）
JP3026352B2 (ja) 1990-09-11 2000-03-27 壽之 松尾 ラットＣＮＰｃＤＮＡ及び前駆体蛋白
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
CA2102808A1 (en) 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
WO1994020534A1 (en) 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
AU4835693A (en) 1993-08-13 1995-03-14 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
CA2174517C (en) 1993-11-12 2007-01-02 David Lowe Receptor specific atrial natriuretic peptides
US5665704A (en) 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JPH10500969A (ja) 1994-06-02 1998-01-27 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング カルジオジラチンフラグメントの調製方法、高度に精製されたカルジオジラチンフラグメント及びそれらの調製のための中間生成物類
JPH0870875A (ja) 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
CA2269656A1 (en) 1996-10-22 1998-04-30 Genentech, Inc. Receptor specific brain natriuretic peptide (bnp)
WO1998035703A2 (en) 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CA2245903A1 (en) 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
CA2260376A1 (en) 1999-02-11 2000-08-11 Universite De Montreal New metalloproteases of the neprilysin family
CA2262056A1 (en) 1999-02-24 2000-08-24 Guy Boileau Composition, methods and reagents for the synthesis of a soluble form of human pex
AU2495200A (en) 1999-03-08 2000-09-28 Genentech Inc. Compositions and methods for the treatment of tumor
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
WO2004011498A2 (en) 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
JP2000327583A (ja) 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1105409B1 (en) 1999-05-17 2006-03-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE19942230C2 (de) 1999-09-03 2003-09-25 Wolf-Georg Forssmann Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
ATE360082T1 (de) 1999-11-16 2007-05-15 Genzyme Corp Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
AU2583901A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
CN1233331C (zh) * 2000-01-10 2005-12-28 李世林 以头部渗透疗法为主治疗癫痫症的药物
JP4237375B2 (ja) 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
US20050142217A1 (en) 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
ES2232613T3 (es) 2000-04-26 2005-06-01 Cellegy Pharmaceuticals, Inc Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno.
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
EP1502604A1 (en) 2000-04-26 2005-02-02 Cellegy Pharmaceuticals, Inc Use of nitric oxide mimetics in cancer treatment
US6830885B1 (en) 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
ATE341631T1 (de) 2000-08-23 2006-10-15 Enobia Pharma Inc Methode und zusammensetzung zur förderung von osteogenese
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
JP2002178279A (ja) 2000-12-12 2002-06-25 Ulvac Japan Ltd 基板搬送方法
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP2002246704A (ja) 2001-02-16 2002-08-30 Philips Japan Ltd 電子装置及び回路装置
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20020183276A1 (en) 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
AU2002367839A1 (en) 2001-07-16 2003-11-17 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US20050202442A1 (en) 2003-12-15 2005-09-15 Morris David W. Novel therapeutic targets in cancer
AU2002356392A1 (en) 2001-12-20 2003-07-09 Phenogene Therapeutiques Inc. Bone polypeptide-1
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US20030158132A1 (en) 2002-01-22 2003-08-21 Genvec, Inc. Method for enhancing bone density or formation
AU2003208228A1 (en) 2002-03-06 2003-09-16 Cellegy Pharmaceuticals, Inc Formulations and methods of using nitric oxide mimetics in cancer treatment
AU2003214214A1 (en) 2002-03-18 2003-10-08 Scios Inc. Method for treating congestive heart failure
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
US20060110359A1 (en) 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
CA2511680A1 (en) 2002-11-18 2004-06-03 Syn X Pharma, Inc. Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
AU2003291867A1 (en) 2002-12-03 2004-06-23 Biomep Inc. Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
EP1583554A2 (en) 2003-01-13 2005-10-12 Gudrun Rappold-Hoerbrand Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
AU2004213432A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Novel therapeutic targets in cancer
US7488713B2 (en) 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
JP2006527190A (ja) 2003-04-17 2006-11-30 サイファージェン バイオシステムズ インコーポレイテッド ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
US20070041972A1 (en) 2003-05-30 2007-02-22 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
CA2570398C (en) 2003-06-17 2020-05-12 Otago Innovation Limited Assessment of skeletal growth using measurements of nt-cnp peptides
EP2308889B1 (en) 2003-06-20 2018-05-23 Mayo Foundation For Medical Education And Research Isoforms of brain natriuretic peptide
WO2005052593A1 (en) 2003-10-29 2005-06-09 The University Of Leicester Detection
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
DK1682583T3 (da) 2003-11-13 2012-05-07 Hanmi Holdings Co Ltd Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
US20080182299A1 (en) 2004-01-27 2008-07-31 Compugent Ltd. Novel brain natriuretic peptide variants and methods of use thereof
EP1730181A2 (en) 2004-01-27 2006-12-13 Compugen USA, Inc. Novel brain natriuretic peptide variants and methods of use thereof
DK1733037T3 (en) 2004-03-11 2015-01-12 Genentech Inc Process for the preparation of polypeptides
EP3620530A1 (en) 2004-03-31 2020-03-11 Kazuwa Nakao Composition for increasing body height
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
JP2005292718A (ja) 2004-04-05 2005-10-20 Furukawa Electric Co Ltd:The 光導波路、光導波路モジュールおよび光導波路の作成方法
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
CA2565410A1 (en) 2004-05-04 2005-11-10 National University Of Singapore Method for expressing sialylated glycoproteins in mammalian cells and cells thereof
MXPA06013029A (es) 2004-05-10 2007-02-12 Novacea Inc Prevencion de la restenosis arterial con compuestos de vitamina d activos.
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
US20070081986A1 (en) 2005-10-07 2007-04-12 Shunji Tomatsu Beta-glucuronidase with an attached short peptide of acidic amino acids
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
WO2006005140A2 (en) 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
WO2006039480A2 (en) 2004-09-29 2006-04-13 The Burnham Institute For Medical Research Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
WO2006060641A2 (en) 2004-12-01 2006-06-08 Genzyme Corporation Methods for targeted delivery of genetic material to the liver
ES2392892T3 (es) 2005-04-07 2012-12-14 Cardiopep Pharma Gmbh Uso de un péptido natriurético para tratar insuficiencia cardiaca
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US20070042957A1 (en) 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
US7470668B2 (en) 2005-08-24 2008-12-30 Enobia Pharma Inc. Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
CA2621264A1 (en) 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Parathyroid hormone analogues and methods of use
WO2007035600A2 (en) 2005-09-16 2007-03-29 Mayo Foundation For Education And Research Natriuretic activities
US20080227713A1 (en) 2005-10-03 2008-09-18 Protter Andrew A Oxidized Human Bnp
RU2316334C2 (ru) 2005-12-19 2008-02-10 Медитек Индастриз ЛЛС Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
AU2007218045B2 (en) 2006-02-20 2011-11-10 Phylogica Limited Method of constructing and screening libraries of peptide structures
US7787945B2 (en) * 2006-03-08 2010-08-31 Neuropace, Inc. Implantable seizure monitor
US8784833B2 (en) 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
US8962697B2 (en) 2006-06-30 2015-02-24 Interface Biologics Inc. Bioreponsive polymers
US7825092B2 (en) 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
WO2008021872A1 (en) 2006-08-08 2008-02-21 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides
CN104193815A (zh) 2006-09-08 2014-12-10 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2295445A1 (en) 2006-09-08 2011-03-16 Mayo Foundation for Medical Education and Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
US7910102B2 (en) 2006-10-25 2011-03-22 Amgen Inc. Methods of using conjugated toxin peptide therapeutic agents
WO2008058016A2 (en) 2006-11-02 2008-05-15 University Of Virginia Patent Foundation Ethoid-containing compounds, methods for preparing ethoid-containing compounds, and methods for use
KR101552843B1 (ko) 2006-11-16 2015-09-14 카이 파마슈티컬즈 부갑상선 기능항진증 및 고칼슘혈증 장애의 치료를 위한 폴리양이온성 칼슘 조절제 펩타이드
KR100856413B1 (ko) * 2006-12-06 2008-09-04 삼성전자주식회사 정착기 및 이를 포함하는 화상형성장치
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
EP2118665B1 (en) 2007-03-12 2012-04-18 Biomedica Medizinprodukte GmbH & Co KG Diagnosis of septic complications
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
US20100297119A1 (en) * 2007-05-11 2010-11-25 Enobia Pharma Inc. Bone targeted alkaline phosphatase, kits and methods of use thereof
WO2008143954A2 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2162464A1 (en) 2007-06-06 2010-03-17 Boehringer Ingelheim International GmbH Natriuretic fusion proteins
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
WO2009006520A1 (en) 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
JP2010532323A (ja) 2007-07-06 2010-10-07 セラテクノロジーズ インコーポレイテッド アルファ−メラニン細胞刺激ホルモン（アルファ−ｍｓｈ）および心房性ナトリウム利尿タンパク質（ａｎｐ）の二機能性融合タンパク質ならびに高血圧および急性腎臓損傷における使用
KR101581476B1 (ko) 2007-07-20 2015-12-30 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 나트륨이뇨성 폴리펩티드
EP2190466A4 (en) 2007-08-10 2011-12-21 Burnham Inst Medical Research Tissue-specific alkaline phosphatase (TNAP) activators and their use
WO2009023270A2 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
RU2010114018A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептид тимозина бета 4 индивидуально или в сочетании с цекропином а в качестве терапевтического средства
ES2575397T3 (es) 2007-09-11 2016-06-28 Cardiopep Pharma Gmbh Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
EP2197469A2 (en) 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection
EP2187941A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a galanin peptide as a therapeutic agent
CA2699169A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
KR20100057063A (ko) 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
US8357656B2 (en) 2007-09-15 2013-01-22 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-C agonists
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
CN101322866A (zh) * 2008-01-11 2008-12-17 梁树立 脑深部癫痫放电引导治疗方法与设备
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
HUE028539T2 (en) 2008-05-23 2016-12-28 Daiichi Sankyo Co Ltd A peptide capable of extending the half-life of an important peptide in plasma
JP2011522824A (ja) 2008-06-06 2011-08-04 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ キメラナトリウム利尿ポリペプチドおよび心臓リモデリングを阻害するための方法
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
KR20220002710A (ko) 2008-06-26 2022-01-06 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
EP2307447B1 (en) 2008-07-02 2016-03-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides with unique pharmacologic profiles
PE20110221A1 (es) 2008-07-23 2011-04-06 Hanmi Science Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales
US20100093678A1 (en) 2008-10-10 2010-04-15 The University Of Georgia Research Foundation, Inc Compositions and methods of the treatment of obesity and osteoporosis
US8642550B2 (en) 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
US8455438B2 (en) 2008-12-29 2013-06-04 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
TW201031752A (en) 2009-01-19 2010-09-01 Hanmi Pharm Ind Co Ltd Method for producing physiologically active protein or peptide using immunoglobulin fragment
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
US20120053123A1 (en) 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
TWI471137B (zh) 2009-05-20 2015-02-01 Biomarin Pharm Inc Ｃ型利鈉胜肽變異體
US8685024B2 (en) 2010-04-14 2014-04-01 Arrowhead Medical Device Technologies, Llc Intramedullary fixation device and methods for bone fixation and stabilization
SG185079A1 (en) * 2010-04-30 2012-12-28 Alexion Pharma Internat Sarl Methods, compositions, and kits for the treatment of matrix mineralization disorders
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
HK1202086A1 (en) 2011-11-10 2015-09-18 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2877247A1 (en) 2012-07-25 2015-06-03 Psioxus Therapeutics Limited Use of s-pindolol for treating cachexia and sarcopenia
WO2014186809A2 (en) 2013-05-17 2014-11-20 The Translational Genomics Research Institute A genetic test to predict patient response to bone morphogenetic protein in arthrodesis
AU2015209783B2 (en) 2014-01-24 2020-10-01 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
HUE051470T2 (hu) 2014-01-24 2021-03-01 Am Pharma Bv Egy alkalikus foszfatáz feldolgozási folyamata
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016061065A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
KR101867134B1 (ko) 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017171871A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS WITH ALKALINE PHOSPHATASES
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018004517A1 (en) 2016-06-27 2018-01-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
EP3592372A4 (en) 2017-03-09 2021-01-13 Alexion Pharmaceuticals, Inc. GLYCOPROTEIN MANUFACTURING PROCESS

Also Published As

Publication number Publication date
US20200093898A1 (en) 2020-03-26
MX389350B (es) 2025-03-19
RU2017123540A (ru) 2019-01-10
ES3038086T3 (en) 2025-10-09
JP2018502836A (ja) 2018-02-01
WO2016090251A1 (en) 2016-06-09
RU2017123540A3 (OSRAM) 2019-07-17
KR20240045379A (ko) 2024-04-05
US10449236B2 (en) 2019-10-22
EP3226891A1 (en) 2017-10-11
CN107405390A (zh) 2017-11-28
EP3226891B1 (en) 2025-06-25
CA2967851A1 (en) 2016-06-09
BR112017011900A2 (pt) 2018-02-27
AU2015357551B2 (en) 2021-02-25
AU2015357551A1 (en) 2017-05-25
RU2708068C2 (ru) 2019-12-04
JP6787894B2 (ja) 2020-11-18
CO2017005034A2 (es) 2017-08-31
MX2017007392A (es) 2019-01-24
US11224638B2 (en) 2022-01-18
US20170360899A1 (en) 2017-12-21
KR20170095278A (ko) 2017-08-22

Similar Documents

Publication Publication Date Title
US11224638B2 (en) Treating seizure with recombinant alkaline phosphatase
AU2008250945B2 (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
JP5986986B2 (ja) 基質石灰化障害を治療する方法、組成物、およびキット
Orimo Pathophysiology of hypophosphatasia and the potential role of asfotase alfa
Sobacchi et al. Role of RANKL signaling in bone homeostasis
CA3246877A1 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT, ALLEVIATION AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH)
BR122024007742A2 (pt) Uso de fosfatase alcalina recombinante no tratamento de ataques
WO2024228791A9 (en) Treating muscle weakness with alkaline phosphatases
HK1191372B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1162589B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1141047B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201203

EEER Examination request

Effective date: 20201203

EEER Examination request

Effective date: 20201203

EEER Examination request

Effective date: 20201203

EEER Examination request

Effective date: 20201203

EEER Examination request

Effective date: 20201203

EEER Examination request

Effective date: 20201203

EEER Examination request

Effective date: 20201203